PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.45%
R&D growth above 1.5x CRVO's 5.59%. Michael Burry would check for spending discipline.
69.30%
G&A growth above 1.5x CRVO's 37.03%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.79%
Operating expenses growth less than half of CRVO's 251.41%. David Dodd would verify sustainability.
30.79%
Total costs growth above 1.5x CRVO's 15.98%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
1.90%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-31.40%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-30.79%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-10.20%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-31.28%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-264.58%
Tax expense reduction while CRVO shows 0.00% growth. Joel Greenblatt would examine advantage.
-31.28%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-21.00%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-22.22%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
7.78%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
7.68%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.